Health
Moderna and Revolution Medicines advance novel cancer therapies following clinical milestones
Recent advances include positive melanoma vaccine trials and FDA approval of a molecular glue pill.
The short version
- Moderna reported positive late-stage trial data for its personalized melanoma vaccine, while the FDA approved Revolution Medicines' molecular glue pill for late-stage prostate cancer.[Business Insider]
- Neither treatment is a standalone cure; both are designed to accompany existing cancer treatments such as immunotherapy or chemotherapy.[Business Insider]
- Moderna's vaccine remains pending FDA review with potential availability by 2027, while Revolution Medicines' pill carries a list price of around $40,000 monthly.[Business Insider]
Key facts
- Moderna reported positive late-stage trial results for its personalized melanoma vaccine on August 19, causing its stock to surge 177%.[Business Insider]
- The FDA approved Revolution Medicines' molecular glue drug, Rasonque, on August 26 to treat late-stage prostate cancer.[Business Insider]
- Rasonque costs roughly $40,000 a month before insurance and is intended for use after chemotherapy.[Business Insider]
- Moderna developed its vaccine technology through a $450 million collaboration with Merck.[Business Insider]
What remains uncertain
- Moderna's melanoma vaccine is not yet approved by the FDA and its 2027 market availability depends on positive regulatory review.[Business Insider]
Sources
Outlet counts describe coverage, not independent confirmation. Reports may share a wire service or original source.
- Two scientists made huge bets on 'impossible' cancer treatments. They're finally paying off.Business Insider metered